References: Pregabalin and gabapentin: harmful, hazardous and dependent use

Australian Institute of Health and Welfare (AIHW). National Drug Strategy Household Survey 2019. Canberra: Australian Government, AIHW; 2020. https://www.aihw.gov.au/about-our-data/our-data-collections/national-drug-strategy-household-survey/2019-ndshs
Australian Institute of Health and Welfare (AIHW). Pharmaceuticals. Alcohol, tobacco & other drugs in Australia. Canberra: Australian Government, AIHW. Updated August 2022. Accessed September 2022. https://www.aihw.gov.au/reports/alcohol/alcohol-tobacco-other-drugs-australia/contents/drug-types/non-medical-use-of-pharmaceutical-drugs
Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49(10):661-9. https://www.ncbi.nlm.nih.gov/pubmed/20818832
Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 2017;27(12):1185-215. https://www.ncbi.nlm.nih.gov/pubmed/28988943
Crossin R, Scott D, Arunogiri S, Smith K, Dietze PM, Lubman DI. Pregabalin misuse-related ambulance attendances in Victoria, 2012-2017: characteristics of patients and attendances. Med J Aust 2019;210(2):75-9. https://www.ncbi.nlm.nih.gov/pubmed/30712302
Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ. Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability. J Clin Pharmacol 2021;61 Suppl 2:S89-S99. https://www.ncbi.nlm.nih.gov/pubmed/34396549
Gomes T, Greaves S, van den Brink W, Antoniou T, Mamdani MM, Paterson JM, et al. Pregabalin and the Risk for Opioid-Related Death: A Nested Case-Control Study. Ann Intern Med 2018;169(10):732-4. https://www.ncbi.nlm.nih.gov/pubmed/30140853
Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin. Addiction 2017;112(9):1580-9. https://www.ncbi.nlm.nih.gov/pubmed/28493329
McNeely J, Halkitis PN, Horton A, Khan R, Gourevitch MN. How patients understand the term "nonmedical use" of prescription drugs: insights from cognitive interviews. Subst Abus 2014;35(1):12-20. https://www.ncbi.nlm.nih.gov/pubmed/24588288
NSW Health. Management of Withdrawal from Alcohol and Other Drugs_Clinical Guidance. St Leonards, NSW: NSW Ministry of Health; 2022. https://www.health.nsw.gov.au/aod/professionals/Pages/clinical-guidance.aspx
Public Health England, NHS England. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. UK: Public Health England and NHS England; 2014. https://www.gov.uk/government/publications/pregabalin-and-gabapentin-advice-for-prescribers-on-the-risk-of-misuse